Patents by Inventor Dirk Gheysen
Dirk Gheysen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160120972Abstract: The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.Type: ApplicationFiled: January 11, 2016Publication date: May 5, 2016Inventors: Benoit BARAS, Dirk GHEYSEN, Isabelle Solange Lucie KNOTT, Jean-Paul PRIEELS, Jean-Francois TOUSSAINT
-
Patent number: 9265821Abstract: The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.Type: GrantFiled: February 16, 2010Date of Patent: February 23, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Benoit Baras, Dirk Gheysen, Isabelle Solange Lucie Knott, Jean-Paul Prieels, Jean-Francois Toussaint
-
Patent number: 8568733Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: GrantFiled: April 9, 2008Date of Patent: October 29, 2013Assignee: GlaxoSmithKline Biologicals SAInventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 8337938Abstract: A method for the preparation of a regenerated silk fibroin solution comprises the steps of: treating silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between ?0.001 and ?0.05 at 25° C.; and subsequently degumming the treated silk or silk cocoons; or alternatively, degumming silk or silk cocoons; and subsequently treating the degummed silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between ?0.001 and ?0.05 at 25° C. The invention also extends to fibroin solution, a fibroin material and an implant useful for cartilage repair.Type: GrantFiled: February 8, 2012Date of Patent: December 25, 2012Assignee: Orthox LimitedInventors: David Philip Knight, Nicholas James Vavasour Skaer, Andrew Michael Collins, Tom Louis Dirk Gheysens, Christopher Holland
-
Publication number: 20120142898Abstract: A method for the preparation of a regenerated silk fibroin solution comprises the steps of: treating silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between ?0.001 and ?0.05 at 25° C.; and subsequently degumming the treated silk or silk cocoons; or alternatively, degumming silk or silk cocoons; and subsequently treating the degummed silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between ?0.001 and ?0.05 at 25° C. The invention also extends to fibroin solution, a fibroin material and an implant useful for cartilage repair.Type: ApplicationFiled: February 8, 2012Publication date: June 7, 2012Inventors: David Philip Knight, Nicholas James Vavasour Skaer, Andrew Michael Collins, Tom Louis Dirk Gheysens, Christopher Holland
-
Patent number: 8128984Abstract: A method for the preparation of a regenerated silk fibroin solution comprises the steps of: treating silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between ?0.001 and ?0.05 at 25° C.; and subsequently degumming the treated silk or silk cocoons; or alternatively, degumming silk or silk cocoons; and subsequently treating the degummed silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between ?0.001 and ?0.05 at 25° C. The invention also extends to fibroin solution, a fibroin material and an implant useful for cartilage repair.Type: GrantFiled: April 30, 2009Date of Patent: March 6, 2012Assignee: Orthox LimitedInventors: David Philip Knight, Nicholas James Vavasour Skaer, Andrew Michael Collins, Tom Louis Dirk Gheysens, Christopher Holland
-
Publication number: 20110318407Abstract: The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.Type: ApplicationFiled: February 16, 2010Publication date: December 29, 2011Inventors: Benoit Baras, Dirk Gheysen, Isabelle Solange Lucie Knott, Jean-Paul Prieels, Jean-Francois Toussaint
-
Publication number: 20110177151Abstract: A method for the preparation of a regenerated silk fibroin solution comprises the steps of: treating silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between ?0.001 and ?0.05 at 25° C.; and subsequently degumming the treated silk or silk cocoons; or alternatively, degumming silk or silk cocoons; and subsequently treating the degummed silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between ?0.001 and ?0.05 at 25° C. The invention also extends to fibroin solution, a fibroin material and an implant useful for cartilage repair.Type: ApplicationFiled: April 30, 2009Publication date: July 21, 2011Inventors: David Philip Knight, Nicholas James Vavasour Skaer, Andrew Michael Collins, Tom Louis Dirk Gheysens, Christopher Holland
-
Publication number: 20110172394Abstract: A method for the preparation of an implantable material for the repair, augmentation or replacement of bone from a fibroin solution, the method comprising the steps of: preparing a gel from the fibroin solution; preparing a material by subjecting the gel to one or more steps of freezing and thawing the gel, wherein the step of preparing the gel from the fibroin solution is performed in the presence of phosphate ions. The material may be treated with calcium ionstoform a fibroin-apatite. A further method comprises the step of treating the material with an isocyanate. The invention also extends to a method for the preparation of an implantable material, wherein a regenerated fibroin solution is used. Also, there is an implantable material and an implant.Type: ApplicationFiled: June 24, 2009Publication date: July 14, 2011Applicant: ORTHOX LIMITEDInventors: David Knight, Nicholas Skaer, Andrew Collins, Tom Louis Dirk Gheysens
-
Publication number: 20080213295Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: ApplicationFiled: April 9, 2008Publication date: September 4, 2008Applicants: CORIXA CORPORATION, SMITHKLINE BEECHAM BIOLOGICALS S.A.Inventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 7375091Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: GrantFiled: May 9, 2001Date of Patent: May 20, 2008Assignees: Corixa Corporation, SmithKline Beecham Biologicals s.a.Inventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 7229623Abstract: The present invention is generally directed to Her-2/neu fusion proteins, nucleic acid molecules encoding Her-2/neu fusion proteins, viral vectors expressing Her-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the Her-2/neu fusion proteins and/or nucleic acid molecules encoding the Her-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the Her-2/neu protein, including for uses in the treatment of malignancies associated with the Her-2/neu oncogene.Type: GrantFiled: August 3, 2000Date of Patent: June 12, 2007Assignee: Corixa CorporationInventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 7198920Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: GrantFiled: January 28, 2000Date of Patent: April 3, 2007Assignees: Corika Corporation, SmithKline Beecham Biologicals, S.A.Inventors: Martin A. Cheever, Dirk Gheysen
-
Publication number: 20020177567Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, Viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: ApplicationFiled: May 9, 2001Publication date: November 28, 2002Inventors: Martin A. Cheever, Dirk Gheysen